

Headquarters: Munich, Germany
Product: deepeye® TPS — AI therapy-planning support for retinal diseases (CE marked Class IIa)
Founded: 2021
Founders / Execs: Manuel Opitz (CEO, Co‑Founder); Ratko Petrovic (CTO, Co‑Founder)
Employee count: 11
Known funding: Seed round announced Nov 7, 2023; lead investor YZR Capital; amount undisclosed
Ophthalmology — therapy planning for retinal diseases (e.g., nAMD).
2021
Medtech / Medical Software
Participating investors reported to include Springboard Health Angels, Bayern Kapital and Arve Capital; amount undisclosed/obfuscated in public profiles.
“Has institutional and angel backing (YZR Capital lead; Springboard Health Angels, Bayern Kapital, Arve Capital participated)”
| Company |
|---|
What we are doing
Our mission is to prevent vision loss and ultimately blindness by developing AI software that assists eye doctors in therapy planning for their patients. We use computer vision deep learning models(AI) trained on thousands of cases and millions of images to identify and predict disease progression. The decision support algorithm targets popular eye diseases like Age-related Macular Degeneration (AMD, 7.5mio affected in Germany alone).
What we are looking for
Your must-haves
Your nice-to-haves
What we offer
Reach out to us with information about your availability, salary expectations and a link to your conclusive profile (GitHub, LinkedIn, CV). Please share with us why you want to help us in preventing blindness with AI.